The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study.
B. de Laat,Vittorio Pengo,Ingrid Pabinger,Jacek Musiał,Alexandre E. Voskuyl,Irene E. M. Bultink,Amelia Ruffatti,Blaž Rozman,T. Kveder,P. De Moerloose,Françoise Boehlen,Jacob H. Rand,Z. Ulcova-Gallova,Koen Mertens,P. G. De Groot +14 more
Reads0
Chats0
TLDR
In this multicenter study, the detection of IgG antibodies that are directed against domain I of beta2GPI proved to be more strongly associated with thrombosis and obstetric complications than those detected using the standard anti‐beta2G PI antibody assay.About:
This article is published in Journal of Thrombosis and Haemostasis.The article was published on 2009-11-01 and is currently open access. It has received 261 citations till now. The article focuses on the topics: Lupus anticoagulant & Antiphospholipid syndrome.read more
Citations
More filters
Journal ArticleDOI
Pathogenesis of antiphospholipid syndrome: understanding the antibodies
TL;DR: Characterization of the molecular basis of the pathogenic mechanisms involved, including the putative second hits and the role of complement activation, might offer an answer to this question.
Journal ArticleDOI
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies
Guillermo Ruiz-Irastorza,M J Cuadrado,Ioana Ruiz-Arruza,Robin L. Brey,Mark Crowther,R. H. W. M. Derksen,Doruk Erkan,Steven A. Krilis,Samuel J. Machin,Vittorio Pengo,Silvia S. Pierangeli,Maria G Tektonidou,Munther A. Khamashta +12 more
TL;DR: This set of recommendations is the result of an effort to produce guidelines for therapy within a group of specialist physicians in Cardiology, Neurology, Hematology, Hem atology, Rheumatology and Internal Medicine, with a clinical and research focus on APS.
Journal ArticleDOI
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends
Maria Laura Bertolaccini,Olga Amengual,Laura Andreoli,Tatsuya Atsumi,Cecilia Beatrice Chighizola,Ricardo Forastiero,Philip G. de Groot,Gabriella Lakos,Marc Lambert,Pier Luigi Meroni,Thomas L. Ortel,Michelle Petri,Anisur Rahman,Robert Roubey,Savino Sciascia,Melissa R. Snyder,Anne E. Tebo,Angela Tincani,Rohan Willis +18 more
TL;DR: This report summarizes the findings, conclusions and recommendations of the "APS Task Force 3-Laboratory Diagnostics and Trends" meeting that took place during the 14th International Congress on Antiphospholipid Antibodies (APLA 2013, September 18-21, Rio de Janeiro, RJ, Brazil).
Journal ArticleDOI
The implications of autoimmunity and pregnancy.
TL;DR: This review focuses on APS, systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), and type 1 diabetes (T1D) and discusses issues of hormones, along with potential long-term effects of the microchimerism phenomenon.
Journal ArticleDOI
Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH.
TL;DR: Coagulation Laboratory, Department of Laboratory Medicine, Ghent University Hospital, Gent, Belgium; †Departments of Medicine and Pathology, Duke University Medical Center, Durham, NC, USA; and ¶Synapse BV, Maastricht, the Netherlands.
References
More filters
Journal ArticleDOI
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan,Alan S. Cohen,James F. Fries,Alfonse T. Masi,Dennis J. McShane,Naomi F. Rothfield,Jane G. Schaller,Norman Talal,Robert Winchester +8 more
TL;DR: The 1971 preliminary criteria for the classification of systemic lupus erythematosus (SLE) were revised and updated to incorporate new immunologic knowledge and improve disease classification and showed gains in sensitivity and specificity.
Journal ArticleDOI
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
Spiros Miyakis,Michael D. Lockshin,Tatsuya Atsumi,D W Branch,Robin L. Brey,Ricard Cervera,R. H. W. M. Derksen,P. G. De Groot,Takao Koike,Pier Luigi Meroni,Guido Reber,Yehuda Shoenfeld,Angela Tincani,Panayiotis G. Vlachoyiannopoulos,Steven A. Krilis +14 more
TL;DR: This document appraise the existing evidence on clinical and laboratory features of APS addressed during the forum and proposes amendments to the Sapporo criteria, including definitions on features ofAPS that were not included in the updated criteria.
Journal ArticleDOI
Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
Ricard Cervera,J.C. Piette,Josep Font,Munther A. Khamashta,Yehuda Shoenfeld,María Teresa Camps,Søren Jacobsen,Gabriella Lakos,Angela Tincani,Irene Kontopoulou-Griva,Mauro Galeazzi,Pier Luigi Meroni,Ronald H. W. M. Derksen,Philip G. de Groot,Erika Gromnica-Ihle,Marta Baleva,Marta Mosca,Stefano Bombardieri,Frédéric Houssiau,Jean-Christophe Gris,Isabelle Quéré,Eric Hachulla,Carlos Vasconcelos,B. Roch,Antonio Fernández-Nebro,Marie Claire Boffa,Graham R. V. Hughes,Miguel Ingelmo +27 more
TL;DR: An association with SLE, the patient's sex, and the patient’s age at disease onset can modify the disease expression and define specific subsets of APS.
Journal ArticleDOI
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
TL;DR: The detection of lupus anticoagulants and, possibly, of immunoglobulin G (IgG) anticardiolipin antibodies at medium or high titers helps to identify patients at risk for thrombosis, however, to take full advantage of the conclusions provided by the available evidence, there is an urgent need to harmonize investigational methods.
Journal ArticleDOI
Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome
TL;DR: A recent systematic review of the literature showed lupus anticoagulants to be risk factors of thrombosis, independent of the type and site of the event, the presence of antiphospholipid antibodies.